# A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

> **NCT07118241** · PHASE2 · RECRUITING · sponsor: **Lubris Bio Pty Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** Recombinant Human Proteoglycan 4
- **DRUG:** Vehicle Control

## Key facts

- **NCT ID:** NCT07118241
- **Lead sponsor:** Lubris Bio Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118241, "A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07118241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*